Actively Recruiting

Phase Not Applicable
Age: 40Years - 85Years
MALE
ID06865430

Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker Therapy

Led by Ankara Training and Research Hospital · Updated on 2025-03-24

82

Participants Needed

1

Research Sites

25 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the use of alpha-blocker therapy to manage dysuria and other irritative urinary symptoms following Holmium Laser Enucleation of the Prostate (HoLEP) surgery for benign prostatic hyperplasia (BPH). Although HoLEP is a minimally invasive and effective treatment, many patients experience irritative symptoms during the first three months after surgery, which can affect quality of life and patient satisfaction. The study aims to clarify the role of alpha-blockers in improving these symptoms after HoLEP, as previous research has focused mostly on other surgical techniques like TURP. The study involves two groups: one will receive alpha-blockers, specifically Tamsulosin Hydrochloride, while the other will not receive this treatment and serve as a comparison group. Participants are randomly assigned to either group. The treatment period focuses on the early postoperative phase, particularly within one month after surgery, when irritative symptoms are commonly reported. Participants will be monitored for symptoms such as dysuria and urgency using a visual analog scale (VAS) scored out of 10 points, as well as the International Prostate Symptom Score (IPSS) one month after surgery. Researchers will assess symptom severity, quality of life, and patient satisfaction. The study will collect these outcome measures to evaluate how alpha-blocker therapy affects urinary symptoms during the early recovery period after HoLEP.

CONDITIONS

Brief Title

Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker Therapy

Who Can Participate

Age: 40Years - 85Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Men over 40 years old and under 85 years old
  • Have undergone Holmium Laser Enucleation of the Prostate (HoLEP) surgery
Not Eligible

You will not qualify if you...

  • Diagnosis of prostate cancer
  • Presence of bladder stones
  • History of urethral stricture
  • Detrusor underactivity diagnosed by urodynamics
  • Previous prostate surgery

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 1 month

Participants receive either alpha blocker therapy or no medication to evaluate effects on dysuria and irritative symptoms after HoLEP surgery.

Visits as needed during the treatment period

Trial Site Locations

Total: 1 location

1

Ankara bilkent city hospital

Ankara, Turkey (Türkiye)

Actively Recruiting

Loading map...

Research Team

K

Kazım Ceviz

A

Ankara Bilkent City Hospital Oncology

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

PREVENTION

Number of Arms

2

Similar Trials

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therap...

Benign Prostatic Hyperplasia

Actively Recruiting

1 location

3D-Ultrasound-Guided Transperineal Microwave Needle Ablation...

Prostate Hyperplasia

Actively Recruiting

1 location

Comparison Between Bipolar Transurethral Resection of the Pr...

Prostate Hyperplasia

Actively Recruiting

6 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here